Singlera Genomics Inc. announced that it has received $60 million in funding from Green Pine Capital Partners Co., Ltd., Shanghai Prosperico Ventures Co., Ltd., Jointown Pharmaceutical Group Co., Ltd., UCF Group, Lilly Asia Ventures, and other investors
March 26, 2018
Share
Singlera Genomics Inc. announced that it has received $60 million in its series A+ round of funding led by existing investor Green Pine Capital Partners Co., Ltd. and new investor Shanghai Prosperico Ventures Co., Ltd. on March 27, 2018. The transaction included participation from existing investor Lilly Asia Ventures and new investors Jointown Pharmaceutical Group Co., Ltd. (SHSE:600998), UCF Group, and other investors.
Jointown Pharmaceutical Group Co., Ltd. is principally engaged in the wholesaling and retailing of pharmaceuticals and medical equipments. The Company is also engaged in the research, development and production of drugs, as well as the provision of relevant value-added services. The Companyâs products mainly include western medicines, proprietary Chinese medicines, Chinese medicine pieces, Chinese herbal medicines, medical equipments, health care products, cosmetics, among others. The Company mainly provides services to direct sales or franchise stores through its retailing businesses.
Singlera Genomics Inc. announced that it has received $60 million in funding from Green Pine Capital Partners Co., Ltd., Shanghai Prosperico Ventures Co., Ltd., Jointown Pharmaceutical Group Co., Ltd., UCF Group, Lilly Asia Ventures, and other investors
JOINTOWN PHARMACEUTICAL GROUP CO., LTD 
